Biogen - BIIB Stock Forecast, Price & News

28 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 8 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.

28 brokers have issued 12 month price objectives for Biogen's stock. Their BIIB share price forecasts range from $217.00 to $370.00. On average, they anticipate the company's share price to reach $309.14 in the next twelve months. This suggests a possible upside of 8.1% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.

Biogen's stock was trading at $276.92 on January 1st, 2023. Since then, BIIB stock has increased by 3.3% and is now trading at $285.94.
View the best growth stocks for 2023 here.

Biogen saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,890,000 shares, an increase of 10.5% from the December 31st total of 1,710,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the short-interest ratio is presently 1.5 days. Approximately 1.3% of the company's shares are short sold.
View Biogen's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 15th 2023.
View our BIIB earnings forecast.

Biogen will be holding an earnings conference call on Wednesday, February 15th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Biogen Inc. (NASDAQ:BIIB) posted its earnings results on Tuesday, October, 19th. The biotechnology company reported $4.77 EPS for the quarter, topping the consensus estimate of $4.09 by $0.68. The biotechnology company had revenue of $2.78 billion for the quarter, compared to the consensus estimate of $2.67 billion. Biogen had a trailing twelve-month return on equity of 21.31% and a net margin of 27.64%. The business's quarterly revenue was down 17.7% compared to the same quarter last year. During the same period last year, the business earned $8.84 earnings per share.
Read the conference call transcript.

Biogen issued an update on its FY 2022 earnings guidance on Tuesday, November, 1st. The company provided earnings per share guidance of $16.50-$17.15 for the period, compared to the consensus EPS estimate of $16.49. The company issued revenue guidance of $10.00 billion-$10.15 billion, compared to the consensus revenue estimate of $10.00 billion.

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.37%), Sumitomo Mitsui Trust Holdings Inc. (0.36%), Parnassus Investments LLC (0.21%), New York State Teachers Retirement System (0.11%), Strs Ohio (0.09%) and Wedge Capital Management L L P NC (0.09%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Stephen A Sherwin and Susan H Alexander.
View institutional ownership trends.

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIIB stock can currently be purchased for approximately $285.94.

Biogen (NASDAQ:BIIB) has a market capitalization of $41.18 billion and generates $10.36 billion in revenue each year. The biotechnology company earns $1.56 billion in net income (profit) each year or $19.64 on an earnings per share basis.

The company employs 9,610 workers across the globe.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.